The Middle East North Africa (MENA) region falls in the low-to-moderate multiple sclerosis (MS) prevalence zone, with prevalence rates slightly lower than Southern Europe but much higher than sub-Saharan Africa. However, there is clearly a trend toward increased MS prevalence over the last few decades, consistent with the globally rising prevalence of the disease. We analyzed all data collected from the MENACTRIMS (Middle East North Africa Committee for Treatment and Research in Multiple Sclerosis) registry by the end of December 2018. A total of 6885 patients were eligible for the study. Overall, the clinical phenotype of MS in the MENA region was not different from the Western phenotype except for earlier age at onset and a more aggressive clinical course leading to earlier disability.
Introduction
Multiple sclerosis (MS) is an immune-mediated demyelinating disorder affecting predominantly patients aged 20-40 years. The incidence and prevalence rates of MS continue to rise worldwide, with the highest rates originating from North America and Europe. 1 Most countries from the MENA (Middle East North Africa) region fall in the lowto-moderate MS prevalence zone, with prevalence rates slightly lower than Southern Europe but much higher than sub-Saharan Africa.
Epidemiology
We reviewed the most relevant epidemiologic studies published in the MENA region, to determine the prevalence of MS in this part of the world (Table 1) . Most epidemiologic studies performed before the year 2000 showed low prevalence rates of MS ranging between 3 and 20/100,000, and came mostly from Saudi Arabia, Iraq, Libya, Kuwait, Tunisia and Jordan. [2] [3] [4] [5] [6] [7] [8] Prevalence started rising during the first decade of the 21 st century, with studies from Kuwait, Saudi Arabia, Palestine and Jordan showing rates in the range of 30-38/100,000. [9] [10] [11] [12] The only exception was Oman, that had a persistently low prevalence rate reaching 4/100,000 in 2005, possibly due to different genetic factors compared with neighboring Arab countries. 13 More recent data from Kuwait, Qatar, Bahrain and United Arab Emirates revealed a further increase, with prevalence rates currently ranging between 55 and 85/ 100,000.
14-18 A single study from Egypt 19 reported in 2013 a low prevalence of 13.7/100,000 in a small city located south of Egypt near the Sudanese border, possibly reflecting the lower prevalence rates seen in African countries. Interestingly, Iran has always shown the highest disease prevalence in the region, increasing from 51.9 in 2010 to 148.1/100,000 in 2017, which might be due to genetic factors related to the different ethnic origins of the Iranian population. 20, 21 It is of note that the methodology to calculate prevalence in the above-mentioned studies varied widely, from national registry-based to hospital or community-based studies, while some of the older studies used the Kurtzke approximation. This approximation estimates MS prevalence by comparing the number of MS and motor neuron disease patients seen during a defined period of time based on the assumption that the prevalence rate of motor neuron disease is fixed at 5/100,000.
There is clearly a trend toward increased MS prevalence in the Middle East over the last few decades, consistent with the globally rising prevalence (Figure 1 24 However, other factors might be contributing to a direct "true" increase in MS incidence in the Middle East, such as increased urbanization and In order to assess the long-term course of the disease, we selected patients with at least 10 years of follow-up since onset of symptoms ( [29] [30] [31] However, the possibility of under-diagnosis of PPMS in our registry could not be ruled out, as the latter's diagnosis is usually more difficult in clinical practice. The NMOSD/MS ratio in our cohort was close to what has been reported in the West. (Table 4) . This is followed in descending frequency by fingolimod, natalizumab, rituximab and dimethyl fumarate. It is of note that locally manufactured generics, mostly Iranian-produced, are used in the MENA region. However, as shown in Table 4 , they account for less than 4% of the total DMTs used. In total, 76.0% of all patients in the registry were on DMTs.
Our study has certain limitations, common to all registry-based studies. The data were collected retrospectively, which might have introduced a bias especially in determining the course of the disease and its phenotype. In addition, and due to the nature of the data collected, there were no unified definitions of clinical phenotypes, disability progression and other clinical parameters. Finally, by choosing patients with a disease duration of at least 10 years, we might have introduced a selection bias toward patients with more aggressive disease, as the latter might be more prone to maintain long-term follow-up.
In conclusion, the prevalence of MS has been steadily rising in the MENA region over the past few decades. The clinical phenotype of MS in the MENA region is similar to what has been described in the West except for an earlier age at onset and a more aggressive clinical course leading to earlier disability.
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